Why the study?
The interplay between alternative isoform splicing and interactions with binding partners in regulating the multifunctionality of myosin VI remained unexplored.
Loss of the tumor suppressor DAB2 may enhance myosin VI-mediated transcription, suggesting a mechanism for increased nuclear myosin VI activity during cancer onset.
Answers are grounded in this paper and cite their sources.
May suggest DAB2-myosin VI axis in cancer transcription; leaves open clinical relevance pending validation.
Myosin VI is involved in many cellular processes ranging from endocytosis to transcription. This multifunctional potential is achieved through alternative isoform splicing and through interactions of myosin VI with a diverse network of binding partners. However, the interplay between these two modes of regulation remains unexplored. To this end, we compared two different binding partners and their interactions with myosin VI by exploring the kinetic properties of recombinant proteins and their distribution in mammalian cells using fluorescence imaging. We found that selectivity for these binding partners is achieved through a high-affinity motif and a low-affinity motif within myosin VI. These two motifs allow competition among partners for myosin VI. Exploring how this competition affects the activity of nuclear myosin VI, we demonstrate the impact of a concentration-driven interaction with the low-affinity binding partner DAB2, finding that this interaction blocks the ability of nuclear myosin VI to bind DNA and its transcriptional activity in vitro . We conclude that loss of DAB2, a tumor suppressor, may enhance myosin VI–mediated transcription. We propose that the frequent loss of specific myosin VI partner proteins during the onset of cancer leads to a higher level of nuclear myosin VI activity.
No takes yet. Share an insight, caveat, or question.
Fili et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: